Immunocore Holdings (IMCR) Share-based Compensation (2023 - 2026)

Immunocore Holdings has disclosed Share-based Compensation across 4 years of filings, most recently posting $6.3 million for Q1 2026.

• Share-based Compensation for Q1 2026 came in at $6.3 million, down 33.59% year-over-year; the trailing twelve-month figure through Mar 2026 was $34.5 million (down 0.59% YoY), and the FY2025 annual result was $37.7 million, up 10.26% from the prior year.
• Share-based Compensation came in at $6.3 million for Q1 2026 at Immunocore Holdings, down from $8.3 million in the prior quarter.
• In the past five years, Share-based Compensation ranged from a high of $10.0 million in Q2 2025 to a low of $6.3 million in Q1 2026.
• The 4-year median for Share-based Compensation is $8.7 million (2024), against an average of $8.5 million.
• Across the five-year window, Share-based Compensation surged 49.98% in 2025 and slumped 33.59% in 2026, its largest moves.
• Immunocore Holdings' Share-based Compensation stood at $7.2 million in 2023, then grew by 20.53% to $8.7 million in 2024, then retreated by 3.78% to $8.3 million in 2025, then slipped by 24.43% to $6.3 million in 2026.
• The last three Share-based Compensation figures came in at $6.3 million (Q1 2026), $8.3 million (Q4 2025), and $9.8 million (Q3 2025), per Business Quant data.